Skip to content Skip to the submenu
Official website of IBSA
(International Blind Sports Federation)
Change font size:
s xl xxl
Change contrast:
High Low
Social media:
Logo RSS Logo twitter Logo Facebook

IBSA Anti-Doping

IBSA, as a signatory of the World Anti-Doping Code, fully supports its purpose which is to:
  • Protect the athlete's fundamental right to participate in doping-free sport and thus promote health, fairness and equality for athletes worldwide;
  • Ensure a harmonized, coordinated and effective anti-doping programme on the international and national level with regard to detection, deterrence and prevention of doping.
IBSA does this through enforcing its anti-doping rules that are in full compliance with the World Anti-Doping Code.
 
IBSA Anti-Doping Rules

IBSA Anti-Doping Rules apply to athletes, competitors, players and their support staff participating in the activities or events of IBSA or any of its national member organisations. Consequently, athletes competing in events organised under the auspices of IBSA may be subject to doping control testing at any time, with or without advance notice.

Therapeutic Use Exemptions

Athletes, like all others, may have illnesses or conditions that require them to take particular medications. It is an athlete’s responsibility to ensure that any medication they take to treat an illness or condition does not fall under the WADA Prohibited List.

Occasionally, athletes may need to take a medication that is on the Prohibited List in order to treat an illness or condition. Before doing so they must apply for, and have granted by an Anti-Doping Organization, a Therapeutic Use Exemption (TUE), which may grant them authorization to take the required medicine.

Athletes competing in IBSA-approved world or regional championships (for example: European, American, Asian or African) who require a TUE should apply to IBSA in good time. A list of IBSA-approved world and regional championships can be seen here: http://www.ibsasport.org/calendar/.
 
Athletes are advised to treat the matter of TUEs very seriously, and in all instances, to seek expert advice. Using a prohibited substance or prohibited method before being awarded a TUE Approval could constitute an anti-doping rule violation.

Links to key anti-doping documents:

- Link to IBSA Anti-Doping rules
- Link to WADA Anti-Doping Code (2015)
- Link to WADA List of Prohibited Substances 2018 (English)
- Link to WADA List of Prohibited Substances 2018 (español)
- Link to WADA List of Prohibited Substances 2018 (français)
- Link to WADA List of Prohibited Substances and Methods 2019 (English)
- Link to WADA List of Prohibited Substances and Methods 2019 (français)
- Link to IBSA Therapeutic Use Exemption Form - Word and PDF
- Link to IBSA Testing Pool for 2018 - Word and PDF
 
Education

The education of athletes, coaches and medical practitioners is critical to the success of any anti-doping programme. Below are a variety of resources to assist all in understanding the processes of doping control and the implications of doping in sport:

WADA Quiz - Test your knowledge of anti-doping,
WADA Doping Control Leaflet (English),
WADA Dangers of Doping Leaflet (English),
WADA Dangers of Doping Leaflet (Other languages),
WADA Doping Control Video.

IBSA Anti-Doping Committee:

Mrs. Hela Kouki Chaouachi (chair)
Mr. Halim Jebali (member)
Mrs. Sana Khelifa (legal advisor)
Mrs. Raja Anane Touzri (member)
Mrs. Daniela Drogge (administrator)

Should you have any questions or need further clarification, please do not hesitate to contact anti-doping@ibsasport.org.

IBSA Testing Pool
 

In the fight against doping, the anti-doping control system has a critically important role to play. These controls not only occur during competition but, in order to combat doping effectively and preventatively, also take place out-of-competition.

While any athlete may be randomly tested, IBSA - according to procedures outlined by WADA - largely focuses its testing on athletes taking part or susceptible to taking part in top-level international competition.

In accordance with WADA’s International Standards for Testing & Investigation, IBSA maintains lists of such players, which are referred to as the IBSA Testing Pool and defined as the pool of highest-priority athletes established separately at the international level by IBSA. They are subject to focused In-Competition and Out-of-Competition Testing as part of IBSA's test distribution plan and therefore are required to provide whereabouts information as provided in Article 5.6 of the Code and the WADA International Standard for Testing and Investigations (2015).

The following IBSA athletes are appointed to the IBSA Testing Pool:
 
  • Vasylysa Kozyreva (IBSA Powerlifting) Ukraine
  • Dursul Hayran (IBSA Powerlifting) Turkey
  • Ahad Javaheri Moghanlou (IBSA Powerlifting) Iran
  • Evgenii Ivanov (IBSA Football) Russia
  • Abderrazak Hattab (IBSA Football) Morocco
  • Paraskevi Naka (IBSA Goalball) Greece
  • Javad Shirdel (IBSA Goalball) Iran
  • Lucia Araujo (IBSA Para Judo) Brasil
  • Feruz Sayidov (IBSA Para Judo) Uzbekistan
  • Luis Daniel Gavilan Lorenzo (IBSA Para Judo) Spain

WADA information on Doping Control Forms (DCFs) and Therapeutic Use Exemption (TUE) (effective as of June 1st 2016)

Mandatory Use of ADAMS for DCFs and TUEs 

In order to reinforce the existing requirements of the 2015 World Anti-Doping Code (Code) (Article 14.5); as well as the International Standards for Testing and Investigations (ISTI) (Article 4.9.1b) and Therapeutic Use Exemptions (ISTUE) (Article 5.4); and, to ensure the transparency of all signatories’ anti-doping programs, the Foundation Board of the World Anti-Doping Agency (WADA) decided at its meeting on 12th May 2016 that:

  • Given that it is a mandatory requirement under the Code and the ISTI to enter all Doping Control Forms (DCFs) and under the ISTUE to enter all Therapeutic Use Exemption (TUE) decisions into ADAMS, all DCFs and TUE decisions shall be entered into ADAMS no later than 15 business days after sample collection or receipt of a TUE decision; and 
  • Failure to do so will result in a declaration of non-compliance, in accordance with the ISO certified WADA process for non-compliance.  
This decision took effect 1 June 2016. 

The TUE form that is mandatory when requesting a TUE can be found in the documents section of this webpage.

WADA’s access to DCFs and TUE information is a key element to ensure effective monitoring of ADOs’ anti-doping programs. A key recommendation of WADA’s recent Independent Commission, which exposed widespread doping in Russian athletics, was for WADA to reiterate to all signatories that they are obliged to “provide complete and timely data for ADAMS”. WADA’s Athlete Committee also strongly supports this requirement.

DCFs must be entered into ADAMS to enable a meaningful steroidal and hematological Athlete Biological Passport’s program to operate globally; to facilitate coordinated test distribution planning; and, to avoid unnecessary duplication in testing by ADOs. Despite this already being a requirement of the Code and ISTI, only 60% of DCFs globally were entered into ADAMS in 2015. 

It is equally important that information about TUEs be made available via ADAMS. This is necessary in order to allow WADA to fulfill its responsibilities under Article 14.5 of the Code with respect to the sharing of data and coordination of anti-doping activities.

ADOs that require assistance with the entry of the required information into ADAMS are invited to contact WADA via ADAMS@wada-ama.org.

IBSA Anti-Doping Statistics 

In 2017 IBSA performed more than 70 in- and out-of-competition tests. We had two Adverse Analytical Findings (AAF). One of them was decided not to be an Anti-Doping Rule Violation. The athlete provided sufficient explanation to explain the AAF. The other case is being forwarded to the Legal and Ethics Committee.

In 2017 IBSA granted 17 Therapuetic Use Exemptions (TUE's).

Anti-Doping Rule Violations

Photo album featuring images of IBSA's Anti-Doping activities.

©2018 IBSA (International Blind Sports Federation) | Created and supported by